Dechra Pharmaceuticals PLC Director/PDMR Shareholding (2354K)
September 19 2016 - 10:10AM
UK Regulatory
TIDMDPH
RNS Number : 2354K
Dechra Pharmaceuticals PLC
19 September 2016
The announcement below replaces an announcement released in
error on 15 September 2016 under RNS number 9802J. That
announcement should have been released on 19 September 2016 in
relation to the grant of awards on 19 September 2016 and not 14
September 2016. In addition, the number of awards for Ian Page have
been amended from 73,667 to 73,260 as below.
19 September 2016
Dechra Pharmaceuticals PLC
(the Company)
Director Shareholding
The Company announces that on 19 September 2016 the following
Directors were granted awards over ordinary shares of 1 pence each
in the Company in connection with the Dechra Long Term Incentive
Plan 2008 (the Plan):
Name of individual Director Type of award Number of
shares subject
to award
-------------------- ---------- ---------------- ----------------
LTIP Award
- nil cost
Ian Page Director option 73,260
-------------------- ---------- ---------------- ----------------
LTIP Award
- Conditional
Tony Griffin Director award 20,858
-------------------- ---------- ---------------- ----------------
The vesting of all the above awards is subject to the
achievement of performance targets. In respect of these grants the
performance conditions will be determined by reference to the
Company's Earnings per Share (EPS) and its Total Shareholder Return
(TSR) relative to constituent companies of the FTSE 250 index
(excluding investment trusts) over a three year performance period.
Both the EPS and TSR elements will be subject to an additional
Return on Capital Employed (ROCE) performance measure. If the ROCE
performance condition is not met, then the LTIP options will lapse
in full.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- ------------------------------------------------------------------
a) Name Ian Page
--- ----------------------------- -----------------------------------
2. Reason for the notification
--- ------------------------------------------------------------------
a) Position/status Director
--- ----------------------------- -----------------------------------
b) Initial notification/ Amendment
amendment Previous notification reference
number: 3684.
The notification should have
been released on 19 September
2016 in relation to the grant
of awards on 19 September
2016 and not 14 September
2016. In addition, the number
of awards have been amended
from 73,667 to 73,260 as below.
--- ----------------------------- -----------------------------------
3. Details of the Issuer
--- ------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ----------------------------- -----------------------------------
b) LEI code N/A
--- ----------------------------- -----------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument ISIN: GB0009633180
Identification
code
--- ----------------------------- -----------------------------------
b) Nature of Grant of nil cost options
the transaction under the Company's Long Term
Incentive Plan
--- ----------------------------- -----------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
Nil cost 73,260
--- ----------------------------- ----------------- ----------------
d) Aggregated N/A
information
* Aggregate volume
* Price
--- ----------------------------- -----------------------------------
e) Date of the 2016.09.19
transaction
--- ----------------------------- -----------------------------------
f) Place of the Outside a trading venue
transaction
--- ----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- ------------------------------------------------------------------
a) Name Tony Griffin
--- ----------------------------- -----------------------------------
2. Reason for the notification
--- ------------------------------------------------------------------
a) Position/status Director
--- ----------------------------- -----------------------------------
b) Initial notification/ Amendment
amendment Previous notification reference
number: 3687.
The notification should have
been released on 19 September
2016 in relation to the grant
of awards on 19 September
2016 and not 14 September
2016.
--- ----------------------------- -----------------------------------
3. Details of the Issuer
--- ------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ----------------------------- -----------------------------------
b) LEI code N/A
--- ----------------------------- -----------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument ISIN: GB009633180
Identification
code
--- ----------------------------- -----------------------------------
b) Nature of Grant of a conditional award
the transaction under the Company's Long Term
Incentive Plan
--- ----------------------------- -----------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
Nil cost 20,858
--- ----------------------------- ----------------- ----------------
d) Aggregated N/A
information
* Aggregate volume
* Price
--- ----------------------------- -----------------------------------
e) Date of the 2016.09.19
transaction
--- ----------------------------- -----------------------------------
f) Place of the Outside a trading venue
transaction
--- ----------------------------- -----------------------------------
For further information, please contact:
Suzana Cross, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAKCDKQBKDFCD
(END) Dow Jones Newswires
September 19, 2016 10:10 ET (14:10 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2023 to Apr 2024